Observational studyMedicina (Kaunas, Lithuania)2019
Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department.
Observational study in Medicina (Kaunas, Lithuania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Telmisartan vs. other antihypertensives on cardiometabolic and vascular outcomes in diabetic hypertension: A randomised trial.The Indian journal of medical research · 2026Trial
- The effects of a pharmacist-led medication review in a nursing home: A randomized controlled trial.Medicine · 2021Trial
- Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.Drug design, development and therapy · 2020Trial
- Comparative analysis of serious adverse effects of antidiabetic drugs and complications associated with type II diabetes mellitus.BMC pharmacology & toxicology · 2026Observational
- South African Herbal Teas and Diabetes-Mediated Mitochondrial Dysfunction: Emerging Evidence and Mechanistic Insights.Journal of food science · 2026Review
- Polypharmacy in Older Adults: A Narrative Review of Clinical Risks, Deprescribing Strategies, and Interdisciplinary Management.Geriatrics (Basel, Switzerland) · 2026Review
- Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review.Journal of bone metabolism · 2026Article
- Glycated hemoglobin (A1c) values and antidiabetic treatment deprescription in hospitalized nonagenarians with type 2 diabetes.Frontiers in public health · 2026Article
- Type 2 diabetes mellitus as a state of altered drug pharmacokinetic-pharmacodynamic parameters: an update on recent developments and clinical implications.Therapeutic advances in endocrinology and metabolism · 2026Review
- Efficacy of FiberMore, an AI-Based mHealth Intervention to Increase Dietary Fiber Intake Among Type 2 Diabetes Patients: Protocol for a Pilot Randomized Controlled Trial.JMIR research protocols · 2025Article
- Small-Molecule Tyrosine Kinase Inhibitors Modulate Glucose Handling in C2C12 Cell Line In Vitro: A Mechanistic Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effects ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Five-year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England.Diabetes, obesity & metabolism · 2025Article
- Comorbidities and use of health services in people with diabetes mellitus according to risk levels by adjusted morbidity groups.BMC endocrine disorders · 2024Article
- The effect of Iranian snake,Heliyon · 2024Article
- Venom-derived peptides for breaking through the glass ceiling of drug development.Frontiers in chemistry · 2024Review
- Drug-related problems among type 2 diabetic patients in Sunwal Municipality of Western Nepal.PloS one · 2024Article
- Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.Frontiers in pharmacology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPolypharmacy heavily impacts the quality of life of patients worldwide. It is a necessary evil in many disorders, and especially in type 2 diabetes mellitus, as patients require treatment both for this condition and its related or unrelated comorbidities. Thus, we aimed to evaluate the use of polypharmacy in type 2 diabetes mellitus vs. non-diabetes patients. MATERIALS AND
methodsA cross-sectional retrospective observational study was conducted. We collected the medical records of patients hospitalized in the Internal Medicine Clinic of the Clinical Emergency Hospital of Bucharest, Romania, for a period of two months (01/01/2018-28/02/2018). Patients diagnosed with type 2 diabetes mellitus were included in the study group, whereas patients who were not diabetic were used as controls.
resultsThe study group consisted of 63 patients with type 2 diabetes mellitus (mean age 69.19 ± 9.67 years, range 46-89 years; 52.38% males). The control group included 63 non-diabetes patients (mean age 67.05 ± 14.40 years, range 42-93 years, 39.68% males). Diabetic patients had more comorbidities (10.35 ± 3.09 vs. 7.48 ± 3.59,
conclusionsPolypharmacy should be an area of serious concern also in type 2 diabetes mellitus, especially in the elderly. In our study, type 2 diabetes mellitus patients received more drugs than their non-diabetes counterparts and were exposed to more drug-drug and food-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.